JP2024525766A - アミロイドベータオリゴマー化の阻害剤及びその治療用途 - Google Patents

アミロイドベータオリゴマー化の阻害剤及びその治療用途 Download PDF

Info

Publication number
JP2024525766A
JP2024525766A JP2024501929A JP2024501929A JP2024525766A JP 2024525766 A JP2024525766 A JP 2024525766A JP 2024501929 A JP2024501929 A JP 2024501929A JP 2024501929 A JP2024501929 A JP 2024501929A JP 2024525766 A JP2024525766 A JP 2024525766A
Authority
JP
Japan
Prior art keywords
amyloid
subject
oligomerization
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525766A5 (https=
Inventor
ビー．シルバーマン リチャード
エル．クレイン ウィリアム
エー．ジョンソン エリザベス
Original Assignee
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2024525766A publication Critical patent/JP2024525766A/ja
Publication of JP2024525766A5 publication Critical patent/JP2024525766A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
JP2024501929A 2021-07-14 2022-07-14 アミロイドベータオリゴマー化の阻害剤及びその治療用途 Pending JP2024525766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203245P 2021-07-14 2021-07-14
US63/203,245 2021-07-14
PCT/US2022/073747 WO2023288284A1 (en) 2021-07-14 2022-07-14 Inhibitors of amyloid beta oligomerization and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024525766A true JP2024525766A (ja) 2024-07-12
JP2024525766A5 JP2024525766A5 (https=) 2025-07-23

Family

ID=84919716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501929A Pending JP2024525766A (ja) 2021-07-14 2022-07-14 アミロイドベータオリゴマー化の阻害剤及びその治療用途

Country Status (6)

Country Link
US (1) US20240325319A1 (https=)
EP (1) EP4370496A4 (https=)
JP (1) JP2024525766A (https=)
CN (1) CN117881650A (https=)
AU (1) AU2022311958A1 (https=)
WO (1) WO2023288284A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019870A1 (en) * 2023-07-20 2025-01-23 Northwestern University Use of neuronal nitric oxide synthase inhibitors in alzheimer's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160039740A1 (en) * 2009-10-29 2016-02-11 Donald R. Kirsch Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20090143433A1 (en) * 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
WO2009036275A1 (en) * 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
ES2668556T3 (es) * 2008-11-20 2018-05-18 Northwestern University Derivados de pirazolona útiles en el tratamiento de esclerosis lateral amiotrófica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160039740A1 (en) * 2009-10-29 2016-02-11 Donald R. Kirsch Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZEINAB BREIJYEH AND RAFIK KARAMAN: "Comprehensive Review on Alzheimer's Disease: Causes and Treatment", MOLECULES (MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE), vol. 25, 5879, JPN6026004557, pages 1 - 28, ISSN: 0005793755 *

Also Published As

Publication number Publication date
US20240325319A1 (en) 2024-10-03
EP4370496A1 (en) 2024-05-22
WO2023288284A1 (en) 2023-01-19
AU2022311958A1 (en) 2024-02-01
EP4370496A4 (en) 2025-07-02
CN117881650A (zh) 2024-04-12

Similar Documents

Publication Publication Date Title
Henstridge et al. Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Sanati et al. Impact of gold nanoparticles on amyloid β-induced Alzheimer’s disease in a rat animal model: Involvement of STIM proteins
AU2017200543B2 (en) Tropinol esters and related compounds to promote normal processing of app
Limbocker et al. Characterization of pairs of toxic and nontoxic misfolded protein oligomers elucidates the structural determinants of oligomer toxicity in protein misfolding diseases
KR20160067103A (ko) 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
JP7285599B2 (ja) 筋萎縮性側索硬化症治療剤及び治療用組成物
JPWO2017104833A1 (ja) 脈絡膜新生血管抑制剤又はドルーゼン抑制剤およびその評価又はスクリーニング方法
CN109073634A (zh) 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
Bulic et al. Chemical biology, molecular mechanism and clinical perspective of γ-secretase modulators in Alzheimer's disease
KR20070116632A (ko) 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CN113164446A (zh) 用于抑制和/或治疗代谢病和/或其临床病症的组合物和方法
JP2024525766A (ja) アミロイドベータオリゴマー化の阻害剤及びその治療用途
WO2017115873A1 (ja) アルツハイマー病の予防及び／又は治療剤
KR102472011B1 (ko) App 의 정상 가공을 촉진하는 화합물
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
CA2807510A1 (en) Inhibitors of erk for developmental disorders of neuronal connectivity
JP2009521470A (ja) シヌクレイン障害の治療
CA2910006A1 (en) Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells
CN109069450A (zh) 神经障碍的新的组合疗法
JPH07188010A (ja) アミロイド形成タンパクの作用を抑制するための医薬組成物
CN121370879A (zh) 治疗边缘型人格障碍的方法
US20240398727A1 (en) (s)-5-(1-(3,5-bis(trifluoromethyl)phenoxy)ethyl)cyclohexane-1,3-dione (nu-9) improves the health of diseased upper motor neurons
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物
WO2025019870A1 (en) Use of neuronal nitric oxide synthase inhibitors in alzheimer's disease
RU2448694C2 (ru) Cпособ противодействия образованию нейротоксичных белков addl (варианты), способ модуляции нейрональной дисфункции или нейротоксичности посредством непептидного соединения и композиция (варианты) на его основе

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210